Scinai Immunotherapeutics Ltd. Sponsored ADR SCNI 深 沪
等待开盘 11-05 09:30:00 美东时间
0.4488
-0.023
-4.92%
华盛通- 最 高0.472
- 今 开0.44
- 成交量 1.47万股
- 最 低 0.44
- 昨 收 0.472
- 总市值 60.73万
- 52周最高 13.00
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 0.3901
- 委 比 -88.68%
- 总股本 135.32万
- 历史最高 62000.00
- 量 比 0.18
- 振 幅 6.78%
- 历史最低 0.3901
- 每 手 1
- 风险率 3.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) on Tuesday announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., entered into a development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. Following the announcement, the stock jumped...
10-14 01:18
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21,...
09-21 19:00
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA). Scholar Rock Holding shares jumpe...
09-14 17:50
美股夜盘 | Scinai Immunotherapeutics Ltd. Sponsored ADR暴升15.66%，最新股价1.92美元
Scinai Immunotherapeutics Ltd. Sponsored ADR暴升15.66%，报1.92美元
09-14 08:01
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc (NYSE:SNOW) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Snowflake reported second-quarter revenue of $1.55 billion, beating analyst estimates of $1.48 billion, according to Benzinga Pro. The AI data cloud compan...
09-03 16:43
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development a...
08-24 19:16
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Scinai Immunotherapeutics shares are surging Friday after it announced fresh financing tied to a private placement and warrant exercise.
04-24 22:25
Scinai Immunotherapeutics Enters Securities Purchase Agreement For Up To 5.21M ADS And Warrants Priced At $0.48 Per Unit
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma
04-24 20:06
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares moved upwards by 145.6%...
04-24 20:05
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer p...
04-24 20:00
